$WOK

HRT FINANCIAL LP purchased $149K of WOK

HRT FINANCIAL LP purchased 1,424,537 shares of WORK Medical Technology Group LTD (WOK) at an average of $0.10 ($0.09–$0.10, $0.15M total) across 2 trades over 2026-06-04 to 2026-06-05.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 8, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$WOK
Bullish
medium confidence
Mentioned
$WOK
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WOKBullishLow
01

Why it matters

The newest information is the disclosed open-market purchase by a 10% owner, which may influence short-term sentiment but does not change company fundamentals on its own.

02

Market read

Traders may treat the buy as a mild positive signal, but the disclosed size suggests limited impact absent other catalysts.

03

What to watch

The filing does not disclose the holder’s cost basis, timing intent, or whether additional buys/sells occurred outside the two reported trades; also, the transaction value is relatively small.

Relevance 5/10Novelty 8/10Timing: Filed June 8, 2026; trades executed June 4–5, 2026.

Background

The filing is an SEC Form 4 insider transaction for WORK Medical Technology Group LTD (WOK).

Company-level read

Ticker impact

$WOKBullishMedium confidence
Context

HRT Financial LP (10% owner) filed a Form 4 for an open-market purchase of 1,424,537 WORK Medical shares for ~$148.9K.

Expected impact

Likely limited near-term impact; may slightly support sentiment rather than drive a repricing.

Evidence & confidence

The article is a primary insider transaction disclosure (Form 4) with a clear buy, but the total value (~$149K) is small versus typical market-cap moves, and no new fundamentals are provided.

Market effects

No sector-level read-through; this is company-specific insider activity without operational or regulatory updates.

None indicated.

None indicated.

Counterpoint

A 10b5-1 plan is explicitly not used, but the trades could still reflect liquidity/portfolio rebalancing rather than a strong forward-looking signal.

Key entities

  • WORK Medical Technology Group LTD

    Subject of the Form 4 insider transaction; trades disclosed for WOK shares.

  • HRT Financial LP

    10% owner who purchased 1,424,537 shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.